Ubrelvy (ubrogepant) stops migraines by blocking a specific pain-signaling protein called CGRP before it can trigger the chain reaction of blood vessel swelling and inflammation that causes migraine pain. It’s an acute treatment, meaning you take it when a migraine starts rather than daily to prevent one. Ubrelvy was the first oral CGRP receptor antagonist approved for this purpose, and it works through a fundamentally different mechanism than older migraine medications like triptans.
The Role of CGRP in Migraines
To understand how Ubrelvy works, it helps to know what happens in your body during a migraine. When a migraine begins, nerve fibers in your trigeminal system (the main pain-sensing network in your head and face) release a protein called CGRP, short for calcitonin gene-related peptide. This protein latches onto receptors on nearby blood vessels and nerve cells, setting off a cascade of events: blood vessels in the brain dilate, inflammatory molecules flood the area, and pain signals fire toward the brain.
CGRP is essentially an amplifier. It doesn’t just trigger one effect; it ramps up multiple processes at once. The vessel dilation creates throbbing pressure. The inflammatory agents make surrounding tissue more sensitive. And the nerve activation keeps relaying pain signals. This is why migraines feel so much worse than a typical headache and why they come bundled with symptoms like nausea, light sensitivity, or sound sensitivity.
How Ubrelvy Blocks This Process
Ubrelvy is a competitive antagonist, which means it physically occupies the same receptor that CGRP needs to bind to. It fits into the receptor with extremely high affinity, effectively locking CGRP out. With CGRP unable to dock, the receptor never activates, and the downstream chain of events never kicks off. Blood vessels don’t dilate as aggressively, inflammatory molecules aren’t released in the same volume, and the relay of pain signals from the trigeminal nerve to the brain is dampened.
Once CGRP binds to its receptor normally, it triggers the production of a signaling molecule called cAMP inside the cell. cAMP is what actually tells the cell to dilate a blood vessel or ramp up inflammation. Ubrelvy prevents cAMP from being generated in the first place, so the cell sits quiet.
Importantly, Ubrelvy does most of its work outside the brain. It has very limited ability to cross into cerebrospinal fluid, so it primarily targets CGRP receptors in the peripheral parts of the trigeminal system: the blood vessels around the skull, nerve endings in the protective tissue surrounding the brain (the dura), and nerve cell clusters in the trigeminal ganglion. This peripheral action is enough to interrupt the migraine process before pain signals reach the brain’s central processing centers.
How It Differs From Triptans
Triptans, the most commonly prescribed acute migraine medications for decades, work by activating serotonin receptors. This causes blood vessels to constrict, which counteracts the dilation that occurs during a migraine. The problem is that this vessel-constricting effect isn’t limited to your head. Triptans can narrow blood vessels elsewhere in the body, which makes them risky for people with heart disease, uncontrolled high blood pressure, or a history of stroke.
Ubrelvy doesn’t constrict blood vessels at all. Instead of forcing vessels to narrow, it prevents them from dilating excessively in the first place by blocking the CGRP signal. This is a meaningful distinction for anyone who can’t safely take triptans due to cardiovascular concerns. It also means Ubrelvy doesn’t carry the same risk of the “chest tightness” sensation that some people experience with triptans.
How Well It Works
In the ACHIEVE II clinical trial, about 22% of people who took the 50 mg dose were completely pain-free at the two-hour mark, compared to 14% who took a placebo. That gap may sound modest, but complete pain freedom is a high bar. A more telling measure is relief from the most bothersome symptom (whether that’s nausea, light sensitivity, or something else): 39% of participants on the 50 mg dose reported that their worst symptom had resolved within two hours, compared to 27% on placebo.
These numbers reflect a single treated attack. For many people, relief continues to build past the two-hour point, and a second dose is an option if the first one isn’t enough. That said, Ubrelvy is not a miracle drug for everyone. Roughly one in five people will be completely pain-free at two hours, which means many will experience partial relief or need to combine it with other strategies.
Dosing and Timing
Ubrelvy comes in 50 mg and 100 mg tablets, taken by mouth with or without food when a migraine begins. If the first dose provides some relief but the migraine isn’t fully resolved, you can take a second dose at least two hours later. The maximum you can take in a 24-hour period is 200 mg total.
The medication has an elimination half-life of roughly 5 to 7 hours, meaning your body clears about half of the drug in that window. Most of the therapeutic effect happens within the first few hours after dosing. Because it’s designed strictly for acute treatment, it’s taken only when a migraine strikes, not on a daily schedule to prevent future attacks.
Side Effects
Ubrelvy’s side effect profile is notably mild. In clinical trials, the only reactions that occurred more frequently than placebo at a rate of 2% or higher were nausea and sleepiness. At the 50 mg dose, 2% of participants reported nausea (the same rate as placebo) and 2% reported sleepiness. At the 100 mg dose, those numbers rose slightly to 4% for nausea and 3% for sleepiness. Dry mouth occurred in about 2% of people on the higher dose.
For context, those rates are low compared to many migraine medications. Triptans commonly cause tingling sensations, chest pressure, dizziness, and fatigue at much higher rates. The trade-off is that Ubrelvy may be somewhat less potent for some people, but for those who experience significant side effects from triptans or who can’t take them safely, the tolerability of Ubrelvy is a real advantage.
Drug Interactions to Be Aware Of
Your body breaks down Ubrelvy using a liver enzyme called CYP3A4. Anything that strongly inhibits this enzyme can cause Ubrelvy to build up to higher-than-intended levels in your bloodstream. Common CYP3A4 inhibitors include certain antifungal medications (like ketoconazole), some antibiotics (like clarithromycin), and HIV protease inhibitors. Grapefruit juice also inhibits this enzyme, though to a lesser degree. If you take any medications regularly, it’s worth confirming they don’t interact before using Ubrelvy.